Medexus Pharmaceuticals Inc. (TSE:MDP) Receives Average Rating of “Buy” from Brokerages

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been given an average rating of “Buy” by the seven ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and four have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is C$5.49.

Several research analysts have weighed in on the company. Ventum Financial lifted their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th. Stifel Canada cut Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Finally, Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd.

Medexus Pharmaceuticals Stock Down 4.0 %

Shares of TSE MDP opened at C$2.87 on Friday. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The company’s fifty day moving average is C$3.58 and its 200-day moving average is C$2.88. The stock has a market cap of C$64.25 million, a price-to-earnings ratio of 13.72 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.